Nasdaq · CIK 0001082554 · PHARMACEUTICAL PREPARATIONS
United Therapeutics Corporation
UTHR chart by TradingView
PRICE HISTORY
LIVE · NASDAQUTHR chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $3.2B
- EBITDA
- $1.6B
- FREE CASH FLOW
- $1.0B
- EPS
- $27.86
- GROSS MARGIN
- 87.92%
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
18.9x
+146%6.9x21.7x
⤢
P / SALES (TTM)
7.9x
+130%2.2x8.8x
⤢
P / BOOK
3.9x
+31%1.3x4.7x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
4.40%
-3.9pp-9.53%14.66%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.8B
+92%⤢
EBITDA (DERIVED)
$0.4B
+44%⤢
NET INCOME
$0.3B
+106%⤢
EPS (DILUTED)
$7.27
+108%⤢
REVENUE GROWTH YOY
-1.92%
-7.6pp-18.43%33.70%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
26.25%
-27.5pp-179.95%65.79%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
20.48%
-18.0pp-6.46%38.55%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN87.30%
OPERATING MARGIN42.23%
NET MARGIN42.51%
FCF MARGIN26.25%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.2B
-6%⤢
STOCK-BASED COMP
$0.0B
-13%⤢
CAPITAL EXPENDITURE
$0.1B
+1087%⤢
SHARES OUTSTANDING
0.05B
-1%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$1.8B
+89%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 100.37%INSIDERS 2.03%OTHER / RETAIL 0.00%1,183 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 12.59% | 5.4M | $2.91B | +4.4% |
| Avoro Capital Advisors LLC | 6.13% | 2.6M | $1.42B | +0.9% |
| Wellington Management Group, LLP | 5.28% | 2.3M | $1.22B | -7.3% |
| Vanguard Portfolio Management LLC | 4.67% | 2.0M | $1.08B | NEW |
| Vanguard Capital Management LLC | 4.56% | 2.0M | $1.05B | NEW |
| State Street Corporation | 4.30% | 1.8M | $993.6M | +0.1% |
| Renaissance Technologies, LLC | 4.17% | 1.8M | $962.9M | -6.4% |
| Geode Capital Management, LLC | 2.87% | 1.2M | $664.4M | +3.4% |
| Janus Henderson Group PLC | 2.02% | 867K | $467.1M | +8.9% |
| AQR Capital Management, LLC | 1.93% | 826K | $445.2M | -35.5% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.